康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00867 康哲药业

午间休市 07-23 12:05:00

12.240

+0.000

0.00%

最高12.440	最低12.110	成交量189.50万
今开12.240	昨收12.240	日振幅2.70%
总市值297.80亿	流通市值297.80亿	总股本24.33亿
成交额2,339万	换手率0.08%	流通股本24.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00867","market":"HK","secType":"STK","nameCN":"康哲药业","latestPrice":12.24,"timestamp":1784779500002,"preClose":12.24,"halted":0,"volume":1895000,"delay":0,"changeRate":0,"floatShares":2433000000,"shares":2433000000,"eps":0.6154,"marketStatus":"午间休市","change":0,"latestTime":"07-23 12:05:00","open":12.24,"high":12.44,"low":12.11,"amount":23388702,"amplitude":0.026961,"askPrice":12.29,"askSize":10000,"bidPrice":12.24,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":0.684786,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784782800000},"marketStatusCode":3,"adr":0,"listingDate":1285603200000,"exchange":"SEHK","adjPreClose":12.24,"dividendRate":0.027461,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.631132,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00867","defaultTab":"news","newsList":[{"id":"2651457047","title":"康哲药业：创新药CMS-D017临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651457047","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651457047?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:17","pubTimestamp":1784114220,"startTime":"0","endTime":"0","summary":"7月15日，康哲药业（00867）发布公告，自主研发的创新药补体因子B抑制剂CMS-D017获得中国国家药品监督管理局签发的药物临床试验批准通知书。该产品旨在治疗年龄相关性黄斑变性（AMD），NMPA同意开展临床试验以评估其安全性和有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807630490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0553294199.USD","00867","LU0738911758.USD","BK1574","IE00BVYPNQ40.USD","SG9999015986.USD","LU0545039389.USD","MEDX","LU2346227817.USD","BK4588","BK1161","IE00BYV24P56.USD","CMS","SG9999004220.SGD","IE00BVYPNP33.GBP","SG9999015945.SGD","BK1593","LU1003077747.HKD","LU0949170772.SGD","BK4208","IE00BGHQDM52.EUR","LU2637428348.USD","LU1894683264.USD","BK1191","159992","LU2488822045.USD","IBBQ","06978","LU2500361329.USD","SG9999015978.USD","LU1894683348.USD","BK4585","LU0661504455.SGD","BMED","IE00BMCWC346.EUR","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180483086","title":"康哲药业获批开展补体因子B抑制剂CMS-D017针对AMD的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1180483086","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180483086?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:35","pubTimestamp":1784111737,"startTime":"0","endTime":"0","summary":"2026年7月15日，康哲药业公告称，其自主研发的口服小分子补体因子B抑制剂CMS-D017胶囊已获国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展针对年龄相关性黄斑变性的安全性与有效性临床研究。CMS-D017采用口服给药，有望提供新的治疗选择。此前，CMS-D017已于2026年1月30日和2月3日分别获得针对阵发性睡眠性血红蛋白尿症和补体参与介导的肾脏疾病的临床试验批准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103161322","title":"康哲药业：国家药监局批准CMS-D017用于年龄相关性黄斑变性的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1103161322","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103161322?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:35","pubTimestamp":1784111720,"startTime":"0","endTime":"0","summary":"中国医药系统控股有限公司宣布，其创新药物CMS-D017已获得国家药品监督管理局的批准，将开展针对年龄相关性黄斑变性的临床试验。这一进展标志着该药物在研发进程中迈出了关键一步，有望为相关眼疾患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQDM52.EUR","BK1593","IE00BVYPNQ40.USD","SG9999004220.SGD","IE00BMCWC346.EUR","LU2488822045.USD","SG9999015986.USD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","SG9999015945.SGD","SG9999015952.SGD","SG9999015978.USD","00867","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651162210?lang=zh_cn&edition=full","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00867","IBB","IE00BVYPNP33.GBP","BK4588","BK4585","GDOC","IE00BYV24P56.USD","BBP","IE00BGHQDM52.EUR","SG9999015986.USD","LFSC","ARTY","BK1593","CHAT","VTHR","SG9999004220.SGD","IE00BMCWC346.EUR","SG9999015978.USD","PBE","SBIO","QTOC","SG9999015945.SGD","SG9999015952.SGD","AGIX","GSKH","WRND","BK1191","LU2488822045.USD","AIPO","IE00BVYPNQ40.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651629631","title":"港股异动 | 英硅智能(03696.HK)早盘涨超7% 与康哲药业在中枢神经系统领域开展AI驱动药物发现合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651629631","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651629631?lang=zh_cn&edition=full","pubTime":"2026-07-13 09:43","pubTimestamp":1783907005,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015986.USD","SG9999015945.SGD","SG9999015952.SGD","00867","IE00BMCWC346.EUR","IE00BVYPNP33.GBP","BK1593","SG9999004220.SGD","SG9999015978.USD","BK1191","LU2488822045.USD","03696","BK1141","IE00BVYPNQ40.USD","IE00BYV24P56.USD","IE00BGHQDM52.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651161179","title":"英硅智能(03696.HK)与康哲药业(00867.HK)达成一项中枢神经系统领域药物研发战略新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651161179","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651161179?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:03","pubTimestamp":1783901028,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","SG9999015978.USD","LU2488822045.USD","SG9999015945.SGD","IE00BYV24P56.USD","SG9999004220.SGD","SG9999015952.SGD","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","03696","IE00BMCWC346.EUR","00867","SG9999015986.USD","BK1593","IE00BGHQDM52.EUR","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180152232","title":"康哲药业6月股份变动月报：总股本维持2,439,528,512股","url":"https://stock-news.laohu8.com/highlight/detail?id=1180152232","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180152232?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:27","pubTimestamp":1782984457,"startTime":"0","endTime":"0","summary":"2026年7月2日，康哲药业公布2026年6月股份变动月报。公告显示，公司法定及注册股本无变化，法定/注册总股本维持为100,000,000美元，对应20,000,000,000股普通股。截至2026年6月30日，普通股已发行股份由上月底的2,438,508,512股减至2,433,131,512股，减少5,377,000股。康哲药业在报告中确认符合香港联合交易所有限公司有关公众持股量的相应规定，所有股份回购均依据相关上市规则和适用法律规范执行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647376479","title":"康哲药业(00867)：李贤良获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2647376479","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647376479?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:33","pubTimestamp":1782732818,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业(00867)发布公告，李贤良先生获委任为独立非执行董事，自2026年6月29日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00867","IE00BYV24P56.USD","BK1593","SG9999015945.SGD","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","IE00BVYPNP33.GBP","BK1191","LU2488822045.USD","SG9999004220.SGD","SG9999015952.SGD","SG9999015986.USD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163936934","title":"康哲药业回购50万股股份，总额约505.89万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163936934","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163936934?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:16","pubTimestamp":1782299769,"startTime":"0","endTime":"0","summary":"康哲药业（00867）于2026年6月24日发布公告，披露公司当日于香港联交所场内回购普通股50万股，占该次股份购回前已发行股本（不包括库藏股）约0.0205%。回购价格区间介乎每股9.94港元至10.22港元，涉资约505.89万港元。\n本次回购完成后，截至2026年6月24日，公司已发行股份总数为24.33131512亿股，库藏股数量为639.7万股。公司股东于2026年4月23日通过购回股份授权，可回购股份总数为2.43952851亿股，至今已购回639.7万股。公司确认，股份回购已获董事会正式授权，遵守香港联交所相关上市规则及其他法律法规。\n本公告由公司秘书吴三燕签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业回购50万股股份，总额约505.89万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645359897","title":"康哲药业(00867.HK)6月24日耗资505.885万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645359897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645359897?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:12","pubTimestamp":1782299572,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015945.SGD","SG9999015952.SGD","00867","IE00BMCWC346.EUR","BK1191","LU2488822045.USD","IE00BVYPNQ40.USD","SG9999015978.USD","IE00BGHQDM52.EUR","SG9999004220.SGD","SG9999015986.USD","BK1593","IE00BYV24P56.USD","IE00BVYPNP33.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029055","title":"康哲药业斯乐韦米单抗注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029055","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645029055?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:59","pubTimestamp":1782125975,"startTime":"0","endTime":"0","summary":"6月22日，康哲药业发布公告称，公司1类治疗用生物制品斯乐韦米单抗（GR1801）注射液（商品名：金速希?）上市许可申请已获得中国国家药品监督管理局（NMPA）批准，于今日获得药品注册证书。产品用于成人狂犬病病毒暴露者的被动免疫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606223778186470.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223778186470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999004220.SGD","SG9999015978.USD","SG9999015952.SGD","IE00BMCWC346.EUR","IE00BYV24P56.USD","SG9999015986.USD","LU2488822045.USD","SG9999015945.SGD","IPOS","BK1191","IE00BGHQDM52.EUR","00867","IE00BVYPNP33.GBP","BK1593","IE00BVYPNQ40.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115053052","title":"康哲药业6月17日回购40万股，耗资约411.12万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115053052","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115053052?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:11","pubTimestamp":1781698309,"startTime":"0","endTime":"0","summary":"康哲药业6月17日公告显示，公司于当日在香港联交所回购普通股40万股，约占当日公司已发行股本0.0164%。本次回购价格介乎每股10.20港元至10.32港元，合计支付约411.12万港元。上述股份回购后，公司发行在外的普通股由24.34亿股减少至24.3363亿股，而库藏股数量由549.7万股增至589.7万股。公司总发行股本保持在24.39528512亿股不变。据公告，回购授权于2026年4月23日通过，公司可根据该授权回购最多2.43952851亿股股份。公司表示，上述交易符合既定的回购授权安排和相关规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业6月17日回购40万股，耗资约411.12万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745441","title":"康哲药业(00867)6月17日斥资411.12万港元回购40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745441","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644745441?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:09","pubTimestamp":1781698195,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业(00867)发布公告，于2026年6月17日，该公司斥资411.12万港元回购40万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU2488822045.USD","SG9999015978.USD","SG9999015945.SGD","IE00BMCWC346.EUR","IE00BYV24P56.USD","00867","BK1593","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","SG9999015986.USD","IE00BGHQDM52.EUR","SG9999004220.SGD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179672205","title":"康哲药业：6月9日回购40.00万股股份，总额约411.28万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179672205","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179672205?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:26","pubTimestamp":1781000788,"startTime":"0","endTime":"0","summary":"6月9日，康哲药业发布公告显示，公司于香港联合交易所回购40.00万股普通股股份，约占本次回购前公司已发行股本的0.0164%。本次回购价格区间为每股10.23港元至10.35港元，合计支出约411.28万港元。回购完成后，公司已发行股本变更为2,434,031,512股，库存股份增至5,497,000股，总股本维持2,439,528,512股。公司进一步确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由公司秘书吴三燕签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康哲药业：6月9日回购40.00万股股份，总额约411.28万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169289651","title":"康哲药业：6月8日回购101.00万股，耗资约1,043.81万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169289651","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169289651?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:36","pubTimestamp":1780914990,"startTime":"0","endTime":"0","summary":"2026年6月8日，康哲药业公告称，于香港联交所场内回购普通股101.00万股，占该公司当日回购前已发行股本约0.0415%。每股回购价介乎每股港币10.18元至10.45元之间，本次回购总金额约为1,043.81万港元。回购完成后，公司于2026年6月8日的已发行股本由2,435,441,512股减少至2,434,431,512股，同时公司库存股数量由4,087,000股增至5,097,000股。购回授权已于2026年4月23日获得通过，授权购回股份总数为243,952,851股。公司确认，本次回购已遵守香港联合交易所《上市规则》及相关法例的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业：6月8日回购101.00万股，耗资约1,043.81万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641485123","title":"康哲药业(00867)6月8日耗资约1043.81万港元回购101万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641485123?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:32","pubTimestamp":1780914751,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业(00867)公布，2026年6月8日耗资约1043.81万港元回购101万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00867","IE00BYV24P56.USD","BK1593","SG9999015945.SGD","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","IE00BVYPNP33.GBP","BK1191","LU2488822045.USD","SG9999004220.SGD","SG9999015952.SGD","SG9999015986.USD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179599633","title":"康哲药业回购101万股股份，涉资约1,065.15万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179599633","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179599633?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:21","pubTimestamp":1780568470,"startTime":"0","endTime":"0","summary":"6月4日，康哲药业公告披露，于2026年6月4日在香港联交所场内回购1,010,000股普通股，占该日现有已发行股本约0.0415%。本次回购价格区间介乎每股港币10.45元至10.63元，合计耗资约港币10,651,460元。此外，公司2026年4月23日通过回购授权，可回购股份总数为243,952,851股。公司确认已遵守香港联交所证券上市规则及相关法律法规的规定。公告由公司秘书吴三燕签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业回购101万股股份，涉资约1,065.15万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149743040","title":"康哲药业回购90万股股份，耗资约968.55万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149743040","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149743040?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:46","pubTimestamp":1780483584,"startTime":"0","endTime":"0","summary":"康哲药业控股有限公司于2026年6月3日发布翌日披露报表，宣布于同日于香港联交所场内回购90万股普通股。根据公告，本次回购占公司现有已发行股本约0.0369%。回购价格介乎每股10.62港元至11.00港元不等，总耗资约9,685,480港元。本次交易后，公司已发行股本由2,437,351,512股降至2,436,451,512股，库藏股数量增至3,077,000股。公司称，此次回购依据2026年4月23日股东大会通过的购回授权进行，该授权允许回购股份总数为243,952,851股，截至目前已累计回购股份3,077,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业回购90万股股份，耗资约968.55万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640890529","title":"康哲药业(00867)6月3日斥资968.55万港元回购90万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640890529","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640890529?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:44","pubTimestamp":1780483479,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业(00867)发布公告，于2026年6月3日，该公司斥资968.55万港元回购90万股股份，每股回购价10.62-11港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015978.USD","SG9999015945.SGD","SG9999015986.USD","00867","BK1191","BK1593","SG9999004220.SGD","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","LU2488822045.USD","IE00BYV24P56.USD","SG9999015952.SGD","IE00BVYPNQ40.USD","IE00BMCWC346.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640597503","title":"医美概念承压 巨子生物(02367)领跌4.08% 机构指敷料药店渠道红利消退、行业进入存量竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2640597503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640597503?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:39","pubTimestamp":1780465177,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念普跌，截至发稿，巨子生物(02367)跌4.08%，医思健康(02138)跌3.66%，复星医药(02196)跌3.16%，康哲药业(00867)跌2.53%，四环医药(00460)跌2.08%，三生制药(01530)跌2.07%。消息面上，华龙证券新近研究指，当前医美行业政策端医保支付监管收紧，医美敷料药店渠道红利消退，行业合规化监管持续深化；医美行业进入存量竞争，循证诊疗、合规经营、精细化运营成为机构发展核心方向。产业端AI智能设备、数字化服务加速在美业线下场景渗透，数智化转型成为行业新趋势，区域美业展会加速全产业链资源整合与模式创新。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982967","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","SG9999015945.SGD","IE00BGHQDM52.EUR","BK1583","IE00BVYPNP33.GBP","BK1593","02138","SG9999004220.SGD","IE00BMCWC346.EUR","SG9999015986.USD","BK1215","IE00BVYPNQ40.USD","BK1161","02196","LU2488822045.USD","SG9999015952.SGD","BK1600","00460","02367","IE00BYV24P56.USD","SG9999015978.USD","HK0000165453.HKD","SG9999004311.SGD","00867","BK1207","BK1511","01530","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cms.net.cn","stockEarnings":[{"period":"1week","weight":-0.0339},{"period":"1month","weight":0.1988},{"period":"3month","weight":-0.0981},{"period":"6month","weight":-0.0981},{"period":"1year","weight":-0.0333},{"period":"ytd","weight":-0.04}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康哲药业控股有限公司是一家主要从事药品生产、营销、推广及销售业务的投资控股公司。该公司的产品包括波依定、优思弗、施图伦滴眼液、喜辽妥、艾蓓尔产品系列及Vmonalisa莫娜丽莎等。其主要在售产品覆盖心脑血管、消化、眼科、皮肤科及医美领域。该公司主要在中国国内和海外市场销售其产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010995},{"month":2,"riseRate":0.6,"avgChangeRate":0.034643},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.007421},{"month":4,"riseRate":0.5,"avgChangeRate":0.025609},{"month":5,"riseRate":0.4375,"avgChangeRate":-0.000081},{"month":6,"riseRate":0.625,"avgChangeRate":0.003785},{"month":7,"riseRate":0.5625,"avgChangeRate":0.003778},{"month":8,"riseRate":0.4,"avgChangeRate":0.021864},{"month":9,"riseRate":0.466667,"avgChangeRate":0.005632},{"month":10,"riseRate":0.5,"avgChangeRate":0.008421},{"month":11,"riseRate":0.5625,"avgChangeRate":0.05425},{"month":12,"riseRate":0.5625,"avgChangeRate":0.034371}],"exchange":"SEHK","name":"康哲药业","nameEN":"CMS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康哲药业,00867,康哲药业股票,康哲药业股票老虎,康哲药业股票老虎国际,康哲药业行情,康哲药业股票行情,康哲药业股价,康哲药业股市,康哲药业股票价格,康哲药业股票交易,康哲药业股票购买,康哲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}